Transplantation of human chromaffin cells for control of intractable cancer pain.

Y. Lazorthes, J. C. Bès, Jacqueline Sagen, M. Tafani, J. Tkaczuk, B. Sallerin, I. Nahri, J. C. Verdié, E. Ohayon, C. Caratero

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.

Original languageEnglish
Pages (from-to)97-100
Number of pages4
JournalActa neurochirurgica. Supplement
Volume64
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

transplantation
Intractable Pain
Chromaffin Cells
Opioid Peptides
Lymphocytes
pain
Morphine
Transplantation
cancer
Tissue
morphine
Narcotics
Granulocyte-Macrophage Colony-Stimulating Factor
cells
Grafts
lymphocytes
Analgesics
Assays
Blood
peptides

ASJC Scopus subject areas

  • Medicine(all)
  • Clinical Neurology

Cite this

Lazorthes, Y., Bès, J. C., Sagen, J., Tafani, M., Tkaczuk, J., Sallerin, B., ... Caratero, C. (1995). Transplantation of human chromaffin cells for control of intractable cancer pain. Acta neurochirurgica. Supplement, 64, 97-100.

Transplantation of human chromaffin cells for control of intractable cancer pain. / Lazorthes, Y.; Bès, J. C.; Sagen, Jacqueline; Tafani, M.; Tkaczuk, J.; Sallerin, B.; Nahri, I.; Verdié, J. C.; Ohayon, E.; Caratero, C.

In: Acta neurochirurgica. Supplement, Vol. 64, 01.12.1995, p. 97-100.

Research output: Contribution to journalArticle

Lazorthes, Y, Bès, JC, Sagen, J, Tafani, M, Tkaczuk, J, Sallerin, B, Nahri, I, Verdié, JC, Ohayon, E & Caratero, C 1995, 'Transplantation of human chromaffin cells for control of intractable cancer pain.', Acta neurochirurgica. Supplement, vol. 64, pp. 97-100.
Lazorthes Y, Bès JC, Sagen J, Tafani M, Tkaczuk J, Sallerin B et al. Transplantation of human chromaffin cells for control of intractable cancer pain. Acta neurochirurgica. Supplement. 1995 Dec 1;64:97-100.
Lazorthes, Y. ; Bès, J. C. ; Sagen, Jacqueline ; Tafani, M. ; Tkaczuk, J. ; Sallerin, B. ; Nahri, I. ; Verdié, J. C. ; Ohayon, E. ; Caratero, C. / Transplantation of human chromaffin cells for control of intractable cancer pain. In: Acta neurochirurgica. Supplement. 1995 ; Vol. 64. pp. 97-100.
@article{834632877b5846399e8300185a29dc59,
title = "Transplantation of human chromaffin cells for control of intractable cancer pain.",
abstract = "Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.",
author = "Y. Lazorthes and B{\`e}s, {J. C.} and Jacqueline Sagen and M. Tafani and J. Tkaczuk and B. Sallerin and I. Nahri and Verdi{\'e}, {J. C.} and E. Ohayon and C. Caratero",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "64",
pages = "97--100",
journal = "Scientific Computing and Instrumentation",
issn = "1078-8956",
publisher = "Springer Wien",

}

TY - JOUR

T1 - Transplantation of human chromaffin cells for control of intractable cancer pain.

AU - Lazorthes, Y.

AU - Bès, J. C.

AU - Sagen, Jacqueline

AU - Tafani, M.

AU - Tkaczuk, J.

AU - Sallerin, B.

AU - Nahri, I.

AU - Verdié, J. C.

AU - Ohayon, E.

AU - Caratero, C.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.

AB - Adrenal medullary chromaffin cells produce high levels of endogenous opioid peptides. Recent data suggest that transplantation injected locally into the spinal subarachnoid space reduced intractable malignant pain. In order to determine the feasibility, the efficacy and the risks of using adrenal medullary tissue for control of irreducible pain, we have developed a transplantation protocol on cancer pain patients selected when they required chronic intrathecal injection of morphine and progressively increasing doses to maintain the level of analgesic effects. At the present time, our clinical trial involves 8 patients. We report here our initial results (mean follow-up: 5 months). The various data collected before and after the intrathecal administration of chromaffin cells included: 1) Pain evaluation over time, with concomitant narcotic intake, 2) CSF sampling through an implanted access port to determine the following biological parameters: biochemical assay for opioid peptides, cell count and phenotyping of lymphocytes, 3) peripheral blood samples for lymphocyte typing. The results confirm the efficacy of adrenal medullary transplantation into spinal CSF for controlling irreducible cancer pain. Complementary intrathecal and oral morphine were totally stopped in 2 cases and stabilized in 5 others. It seems essential to have an important volume of grafted tissue to achieve analgesia with high levels of metenkephalin in CSF. A progressive decrease in metenkephalin release was observed from 2 to 4 months after the transplantation. Two patients with a long-term follow-up (8 and 12 months) needed another intrathecal chromaffin cell graft.

UR - http://www.scopus.com/inward/record.url?scp=0029443884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029443884&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 97

EP - 100

JO - Scientific Computing and Instrumentation

JF - Scientific Computing and Instrumentation

SN - 1078-8956

ER -